ofatumumab
Sign in to saveAlso known as OMB157
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458269271
- Drug.type
- mab
- Drug.image
- Ofatumumab_3GIZ.png
- Drug.caption
- Fragment antigen-binding of ofatumumab ()
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- CD20
- Drug.tradename
- Arzerra, Kesimpta
- Drug.MedlinePlus
- a621050
- Drug.DailyMedID
- Ofatumumab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Intravenous (Arzerra), subcutaneous (Kesimpta)
- Drug.ATC_supplemental
- (Arzerra), (Kesimpta)
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
via Wikipedia infobox
Research
1,064 papersvia PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- carbon
- Has use
- medication
Show 6 more facts
- NCI Thesaurus ID
- C66952
- subject has role
- monoclonal antibody
- medical condition treated
- chronic lymphocytic leukemia
- Commons category
- Ofatumumab
- World Health Organisation international non-proprietary name
- ofatumumab
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~6 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Mechanism
- History
- Society and culture
- Economics
- References
- Further reading
- External links
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab.
The most common side effects for ofatumumab (Kesimpta) include upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions. The most common side effects for ofatumumab (Arzerra) include infusion reactions and neutropenia.
Excerpted from Wikipedia’s “ofatumumab” article, available under the CC BY-SA 4.0 licence.